Dilaforette is granted SEK 2.85m for development of sevuparin for the treatment of severe malaria

STOCKHOLM – November 2, 2012. Dilaforette announces today that it has been grantedSEK 2.85m from the Swedish Governmental Agency for Innovation Systems, Vinnova, for the development of sevuparin, a new potential treatment for severe malaria.Sevuparin is intended as an adjunctive therapy to anti-parasite medicines in order to prevent the infected red blood cells from obstructing blood vessels and thereby reducing mortality. Each year nearly 10 million people are diagnosed with severe malaria and about one million die of the disease. The grant from Vinnova will be used for process and